SK Biopharmaceuticals stock price

SK바이오팜KRX:326030 · KOSPI · Healthcare · sector #23
₩73,000-3.95%
2026-10-08 close
Loading chart…

SK Biopharmaceuticals's chart data is dated 2026-10-08. There is no active technical signal. There are 0 published signal records.

SK Biopharmaceuticals last closed at ₩73,000 (-3.95%) on 2026-10-08. Listed on KOSPI. Trailing 12 months PER is 14.2×. Its overall grade ranks 107 of 308 stocks in Healthcare.

About this company

SK Biopharmaceuticals last closed at ₩73,000 (-3.95%) on 2026-10-08. Listed on KOSPI.

Details →

Reported results

Details →

Position in sector

Healthcare · Overall B+ · 107/308

Valuation grade F

Details →

Recent filings

DART · received recent list, not a complete filing history. Factual information, not investment advice.

Details →

Related stocks

  • 국내 바이오/제약 성장주로 파이프라인·상업화 측면에서 투자자 비교 대상

  • 유한양행Competitor

    국내 신약개발·기술수출 중심 기업으로 동종 업종 경쟁/비교 대상

  • 한미약품Competitor

    신약 R&D와 글로벌 기술이전 경쟁에서 주요 국내 비교 대상

Details →

ETFs holding this stock

KIWOOM 의료AI · TIGER 200 헬스케어 · RISE 헬스케어

Details →
About SK Biopharmaceuticals
What technical signals does SK Biopharmaceuticals (326030) have?
SK Biopharmaceuticals current technical signals: no active technical signal.
Is SK Biopharmaceuticals a cup-and-handle pattern?
No. SK Biopharmaceuticals has no valid Cup signal right now.
What published figures are available for SK Biopharmaceuticals?
Market cap: KRW 5.7T. Trailing 12 months PER: 14.2×. Latest quarter PBR: 5.57×. Dividend yield: 0.00%.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Major stocks in the same sector

2026-10-09 dataset

Turn what you saw on this name into a strategy

Ask Q about SK Biopharmaceuticals, or open the plan table on the main site.

From the names you found to a trading rule

Tell Q about the stocks you found to place orders with your conditions.

See plans ↗

SK Biopharmaceuticals notifications

Quantus Signal · live data · not investment advice · Privacy Policy